Bone Mineral Density, Body Composition, and Metabolic Health of Very Low Birth Weight Infants Fed in Hospital Following Current Macronutrient Recommendations during the First 3 Years of Life.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
20 Mar 2021
Historique:
received: 31 01 2021
revised: 14 03 2021
accepted: 17 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 29 5 2021
Statut: epublish

Résumé

The present study longitudinally evaluated growth, bone mineral density, body composition, and metabolic health outcome in very low birth weight (VLBW) infants whose in-hospital target nutrient intake was within recent recommendations. From six months to three years, bone mineral density (dual-energy X-ray absorptiometry, DXA), body composition, and metabolic health outcome were compared with a reference group of term infants. The aim was to test whether in-hospital achieved weight gain until 36 weeks of gestation (light or appropriate for term equivalent age; LTEA or ATEA) predicts later growth, bone mineral density (BMD), abdominal obesity, or metabolic health outcomes such as insulin resistance, relative to term infants, during the first three years of life. Target in-hospital energy and protein intake was not achieved. Growth in weight, length and head circumference, mid arm circumference, adiposity, fat free mass (FFM), and bone mineralization in VLBW infants was less than those in term infants and influenced by nutritional status at discharge. Preterm infants had poorer motor and cognitive outcomes. Post-discharge body composition patterns indicate FFM proportional to height but lower fat mass index in LTEA preterm infants than term infants, with no evidence of increased truncal fat in preterm infants. The hypothesis of early BMD catch-up in VLBW infants after discharge was not supported by the present data. The clinical significance of these findings is unclear. The data may suggest a reduced obesity risk but an increased osteoporosis risk. Since postnatal growth restriction may have permanent negative health effects, LTEA VLBW infants would especially appear to benefit from targeted preventive interventions. Further follow-up of the infants is required.

Identifiants

pubmed: 33804764
pii: nu13031005
doi: 10.3390/nu13031005
pmc: PMC8003951
pii:
doi:

Substances chimiques

Insulin-Like Growth Factor I 67763-96-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fondo de Investigacion Sanitaria
ID : PI041631

Références

Pediatrics. 2009 Jan;123(1):e101-9
pubmed: 19117831
JAMA. 2009 Nov 25;302(20):2235-42
pubmed: 19934425
Clin Perinatol. 2014 Jun;41(2):309-21
pubmed: 24873834
Arch Dis Child. 2006 Jul;91(7):612-7
pubmed: 16790722
J Pediatr. 2013 Mar;162(3 Suppl):S7-16
pubmed: 23445851
J Pediatr Endocrinol Metab. 2012;25(9-10):951-5
pubmed: 23426825
J Pediatr. 2019 Jul;210:69-80.e5
pubmed: 30992219
Neonatology. 2018;114(2):177-180
pubmed: 29920494
Arch Dis Child. 2016 Nov;101(11):1026-1031
pubmed: 27288431
Am J Clin Nutr. 2005 Feb;81(2):480-7
pubmed: 15699238
Pediatrics. 1993 Mar;91(3):617-23
pubmed: 8441569
Behav Brain Res. 1992 Jul 31;49(1):1-6
pubmed: 1388792
Obstet Gynecol. 1996 Feb;87(2):163-8
pubmed: 8559516
J Clin Endocrinol Metab. 2012 Dec;97(12):4498-506
pubmed: 22993033
Neonatology. 2014;106(1):30-6
pubmed: 24776717
Nutrients. 2013 Jun 05;5(6):2019-27
pubmed: 23739143
Am J Clin Nutr. 1998 Mar;67(3):465-72
pubmed: 9497191
J Bone Miner Res. 1999 May;14(5):810-20
pubmed: 10320530
Acta Paediatr. 2015 Oct;104(10):974-86
pubmed: 26179961
Osteoporos Int. 2013 Jan;24(1):7-18
pubmed: 22930242
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2491-2500
pubmed: 28453635
J Clin Endocrinol Metab. 2007 Sep;92(9):3429-35
pubmed: 17566098
Osteoporos Int. 2009 Nov;20(11):1903-10
pubmed: 19308302
Arch Dis Child Fetal Neonatal Ed. 1999 May;80(3):F188-91
pubmed: 10212079
Clin Endocrinol (Oxf). 2008 May;68(5):773-9
pubmed: 17980003
Calcif Tissue Int. 2016 Feb;98(2):105-13
pubmed: 26472429
Nutrition. 2013 Nov-Dec;29(11-12):1321-5
pubmed: 24012390
Pediatr Res. 1994 Jan;35(1):125-9
pubmed: 8134190
J Clin Endocrinol Metab. 2008 Feb;93(2):452-8
pubmed: 18029462
World Rev Nutr Diet. 2013;106:26-32
pubmed: 23428677
World Rev Nutr Diet. 2013;106:181-8
pubmed: 23428699
Acta Paediatr Suppl. 1994 Dec;405:117-22
pubmed: 7734783
Horm Res Paediatr. 2020;93(3):144-153
pubmed: 32846418
Bone Rep. 2018 Dec 12;10:100189
pubmed: 30627597
Mol Metab. 2015 Mar 21;4(6):437-60
pubmed: 26042199
Am J Clin Nutr. 2004 Aug;80(2):436-40
pubmed: 15277167
Cytokine. 2013 Oct;64(1):448-53
pubmed: 23726672
Curr Diab Rep. 2019 Jul 20;19(8):60
pubmed: 31327060
PLoS One. 2019 Mar 7;14(3):e0213267
pubmed: 30845245
J Pediatr Gastroenterol Nutr. 2010 Jan;50(1):85-91
pubmed: 19881390
Bone. 2001 Nov;29(5):424-7
pubmed: 11704492
JAMA Pediatr. 2017 Jan 1;171(1):16-22
pubmed: 27893064
Arch Dis Child Fetal Neonatal Ed. 2008 Mar;93(2):F108-14
pubmed: 17660214
Ann Pediatr Endocrinol Metab. 2019 Mar;24(1):15-21
pubmed: 30943675
J Clin Endocrinol Metab. 2004 Jul;89(7):3486-95
pubmed: 15240636
PLoS Med. 2009 Aug;6(8):e1000135
pubmed: 19707270
J Pediatr. 2001 Jan;138(1):92-100
pubmed: 11148519
Ann Surg. 1978 Jan;187(1):1-7
pubmed: 413500
J Pediatr Endocrinol Metab. 2009 Sep;22(9):781-94
pubmed: 19960888
Clin Nutr. 2018 Dec;37(6 Pt B):2303-2305
pubmed: 30471662
J Osteoporos. 2012;2012:672403
pubmed: 23091773
J Clin Endocrinol Metab. 2012 Apr;97(4):1294-302
pubmed: 22399507
Arch Dis Child Fetal Neonatal Ed. 2019 May;104(3):F235-F241
pubmed: 30135111
J Pediatr. 2016 Aug;175:93-99.e1
pubmed: 27318373
Pediatrics. 2012 Sep;130(3):e640-9
pubmed: 22891222
Pediatrics. 2009 Aug;124(2):649-57
pubmed: 19651583
Arch Ophthalmol. 1984 Aug;102(8):1130-4
pubmed: 6547831
Early Hum Dev. 2008 Aug;84(8):555-9
pubmed: 18329828
Acta Paediatr. 2002;91(6):680-3
pubmed: 12162602
Growth Horm IGF Res. 2004 Jun;14 Suppl A:S130-5
pubmed: 15135795
PLoS One. 2019 May 7;14(5):e0216048
pubmed: 31063464

Auteurs

Walter Mihatsch (W)

Department of Pediatrics, Ulm University and Neu-Ulm University of Applied Sciences, 89231 Neu-Ulm, Germany.

Izaskun Dorronsoro Martín (I)

Department of Neonatology, Hospital Universitario La Paz, Department of Pediatrics, Universidad Autonoma de Madrid, 28046 Madrid, Spain.

Vicente Barrios-Sabador (V)

Department of Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, Department of Pediatrics, Universidad Autónoma de Madrid, 28039 Madrid, Spain.
CIBER Fisiopatología de la obesidad y nutrición (CIBERobn), Instituto de Salud Carlos III, 28029 Madrid, Spain.

María L Couce (ML)

Neonatology Department, University Clinical Hospital of Santiago de Compostela, IDIS-Health Research Institute of Santiago de Compostela, Universidad de Santiago de Compostela, 15704 Santiago de Compostela, Spain.

Gabriel Á Martos-Moreno (GÁ)

Department of Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, Department of Pediatrics, Universidad Autónoma de Madrid, 28039 Madrid, Spain.
CIBER Fisiopatología de la obesidad y nutrición (CIBERobn), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Jesús Argente (J)

Department of Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, Department of Pediatrics, Universidad Autónoma de Madrid, 28039 Madrid, Spain.
CIBER Fisiopatología de la obesidad y nutrición (CIBERobn), Instituto de Salud Carlos III, 28029 Madrid, Spain.
IMDEA Institute, 28049 Madrid, Spain.

José Quero (J)

Department of Neonatology, Hospital Universitario La Paz, Department of Pediatrics, Universidad Autonoma de Madrid, 28046 Madrid, Spain.

Miguel Saenz de Pipaon (M)

Department of Neonatology, Hospital Universitario La Paz, Department of Pediatrics, Universidad Autonoma de Madrid, 28046 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH